GEA 3162

Drug Profile

GEA 3162

Latest Information Update: 27 Aug 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GEA Farmaceutisk Fabrik AS
  • Class Anticoagulants; Antihypertensives; Small molecules
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 23 Feb 1999 GEA is now a subsidiary of Hexal
  • 20 Feb 1997 New profile
  • 20 Feb 1997 Preclinical development for Hypertension in Denmark (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top